Current Landscape of Immunotherapy in Breast Cancer: A Review.
Current Landscape of Immunotherapy in Breast Cancer: A Review.
复制标题
DOI：
10.1001/jamaoncol.2018.7147
复制
发表时间：
2019-08-01
期刊：
影响因子：
28.4
通讯作者：
Mittendorf EA
中科院分区：
文献类型：
--
作者：
Adams S;Gatti-Mays ME;Kalinsky K;Korde LA;Sharon E;Amiri-Kordestani L;Bear H;McArthur HL;Frank E;Perlmutter J;Page DB;Vincent B;Hayes JF;Gulley JL;Litton JK;Hortobagyi GN;Chia S;Krop I;White J;Sparano J;Disis ML;Mittendorf EA
人们对使用免疫疗法治疗乳腺癌有着极大的兴趣，这一点可以从本叙述性综述时正在进行的290多项临床试验中得到证明。这篇综述的目的是描述乳腺癌免疫治疗的现状，强调其在早期和转移性疾病中的潜力。在2018年4月24日搜索ClinicalTrials.gov和截至2018年6月30日的PubMed以识别乳腺癌免疫治疗试验后，我们发现免疫检查点阻断（ICB）是乳腺癌中研究最多的免疫治疗形式。使用ICB作为单药治疗在乳腺癌患者中实现了客观缓解，在早期治疗中使用时观察到更高的缓解率。对于有反应的患者，这些反应是持久的。最近的数据表明，ICB与化疗联合使用时具有临床疗效。正在进行的研究正在评估将ICB与其他化疗药物、靶向治疗、疫苗和局部消融治疗配对以增强反应的联合策略。迄今为止，尚未建立ICB反应的可靠预测生物标志物。预计联合治疗策略将是乳腺癌免疫治疗的前进方向，对肿瘤，微环境和宿主因素的了解将为治疗组合决策提供信息。结合适当终点和相关研究的深思熟虑的研究设计对于确定增强针对乳腺肿瘤的免疫反应的最佳策略至关重要。
There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at the time of this narrative review. The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease. After searching ClinicalTrials.gov on April 24, 2018, and PubMed up to June 30, 2018, to identify breast cancer immunotherapy trials, we found that immune checkpoint blockade (ICB) is the most investigated form of immunotherapy in breast cancer. Use of ICB as monotherapy has achieved objective responses in patients with breast cancer, with higher rates seen when administered in earlier lines of therapy. For responding patients, those responses are durable. More recent data suggest clinical efficacy when ICB is given in combination with chemotherapy. Ongoing studies are evaluating combination strategies pairing ICB with additional chemotherapeutic agents, targeted therapy, vaccines, and local ablative therapies to enhance response. To date, robust predictive biomarkers for response to ICB have not been established. It is anticipated that combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding of tumor, microenvironment, and host factors informing treatment combination decisions. Thoughtful study design incorporating appropriate end points and correlative studies will be critical in identifying optimal strategies for enhancing the immune response against breast tumors.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-09-0265
发表时间：
2009-09-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Dewan MZ;Galloway AE;Kawashima N;Dewyngaert JK;Babb JS;Formenti SC;Demaria S
通讯作者：
Demaria S
DOI：
10.1002/cjp2.25
发表时间：
2015-10
期刊：
The journal of pathology. Clinical research
影响因子：
--
作者：
Budczies J;Bockmayr M;Denkert C;Klauschen F;Lennerz JK;Györffy B;Dietel M;Loibl S;Weichert W;Stenzinger A
通讯作者：
Stenzinger A
影响因子：
45.3
作者：
Adams, Sylvia;Gray, Robert J.;Badve, Sunil S.
通讯作者：
Badve, Sunil S.
影响因子：
10.1
作者：
Barker CA;Postow MA;Khan SA;Beal K;Parhar PK;Yamada Y;Lee NY;Wolchok JD
通讯作者：
Wolchok JD
影响因子：
51.1
作者：
Denkert, Carsten;von Minckwitz, Gunter;Loibl, Sibylle
通讯作者：
Loibl, Sibylle